Extranodal extension (ENE) is known to be associated with poor outcomes in head and neck squamous cell carcinoma. The objective of this study is to examine the impact of extent of ENE on survival in oropharyngeal carcinoma in the human papillomavirus (HPV) era.
Study Design
Retrospective database review.
Setting
Review of the National Cancer Database.
Subjects and Methods
The National Cancer Database was used to examine surgically treated head and neck squamous cell carcinoma of the tonsil and base of tongue from 2010 to 2015. Nodes available for pathologic examination were classified as ENE negative (–), ENE clinically (+), or ENE (+) on pathology only. The primary outcome was overall survival. Cox regression modeling was used to examine the effect of ENE on survival while controlling for patient demographics, HPV status, stage, adjuvant radiation, and chemotherapy.
Results
Of the 66,106 patients identified, 16,845 were treated with surgery ± adjuvant therapy, 8780 of whom were known HPV+. Overall 5-year survival for this group was 86%. Documented ENE was associated with over a 60% decrease in survival for clinical (hazard ratio [HR], 1.63) and pathologic (HR, 1.62) ENE compared to negative ENE, after adjustment for stage, adjuvant radiation ± chemotherapy, HPV, and other variables. No significant differences were found between clinical and pathologic ENE (HR, 1.001).
Conclusion
While both surgically resected clinical and pathologic ENE are associated with decreased survival, no significant differences are observed between the two. The impact of these observations on potential de-escalation therapeutic strategies requires further study.
PollaersKHinton-BayreAFriedlandPLFarahCS. AJCC 8th edition oral cavity squamous cell carcinoma staging—is it an improvement on the AJCC 7th edition?Oral Oncol. 2018;82:23-28.
2.
ShevachJBossertABakstRL, et al. Extracapsular extension is associated with worse distant control and progression free survival in patients with lymph node–positive human papillomavirus–related oropharyngeal carcinoma. Oral Oncol. 2017;74:56-61.
3.
WoolgarJARogersSNLoweDBrownJSVaughanED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol. 2003;39:130-137.
4.
JohnsonJTBarnesLMyersENSchrammVLBorochovitzDSiglerBA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol Head Neck Surg. 1981;107(12):725-729.
5.
CarterRLBarrLCO’BrienCJSooK-CShawHJ. Transcapsular spread of metastatic squamous cell carcinoma from cervical lymph nodes. Am J Surg. 1985;150(4):495-499.
6.
JohnsonJTMyersENBedettiCDBarnesLSchrammVLThearleP. Cervical lymph node metastasis: Incidence and implications of extracapsular carcinoma. Arch Otolaryngol Head Neck Surg. 1985;111:534-537.
7.
AlviAJohnsonJT. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck. 1997;19(6):500-505.
8.
GreenbergJSFowlerRGomezJ, et al. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer. 2003;97(6):1464-1470.
9.
CooperJSPajakTFForastiereA, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperarative radiochemotherapy. Head Neck. 1998;20:588-594.
10.
BernierJDomengeCOzsahinEM, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952.
11.
CooperJSPajakTFForastiereA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-1944.
12.
WestraWH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009;3(1):78-81.
13.
MorkJLieKGlattreE, et al. Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125-1131.
14.
GillisonMLKochWMCaponeRB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Nat Cancer Inst. 2000;92(9):709-720.
15.
ChannirHIKissKRubekN, et al. Comparison of clinical, radiological and morphological features including the distribution of HPV E6/E7 oncogenes in resection specimens of oropharyngeal squamous cell carcinoma. Oral Oncol. 2018;87:163-170.
16.
AngKKHarrisJWheelerR, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
17.
BossiPOrlandiEMiceliR, et al. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. Ann Oncol. 2014;(25):694-699.
18.
De FeliceFtomboliniVValentiniV, et al. Advances in the management of HPV-related oropharyngeal cancer. J Oncol. 2019;2019:9173729.
19.
FundakowskiCELangoM. Considerations in surgical versus nonsurgical management of HPV positive oropharyngeal cancer. Cancers Head Neck. 2016;1:6.
20.
LindelKBeerKTLaissueJGreinerRHAebersoldDM. Human papillomavirus positive squamous cell carcinoma of the oropharynx. Cancer. 2001;92(4):805-813.
21.
LiWThompsonCHO’BrienCJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. 2003;106(4):553-558.
22.
DhanireddyBBurnettNPSanampudiS, et al. Outcomes in surgically resectable oropharynx cancer treated with transoral robotic surgery versus definitive chemoradiation. Am J Otolaryngol. 2019;40(5):673-677.
23.
QuonHCohenMAMontoneKTZioberAWeinsteinGSO’MalleyBW. Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16(INK4a) on treatment outcomes. Laryngoscope. 2013;123(3):635-640.
24.
RichJTMilovSLewisJSThorstadWLAdkinsDRHaugheyBH. Transoral laser microsurgery (TLM) ± adjuvant therapy for advances stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope. 2009;119(9):1709-1719.
25.
CohenMAWeinsteinGSO’MalleyBWFeldmanMQuonH. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck. 2011;33(4):573-580.
26.
JacksonRSSinhaPZengaJ, et al. Transoral resection of human papillomavirus (HPV)–positive squamous cell carcinoma of the oropharynx: outcomes with and without adjuvant therapy. Ann Surg Oncol. 2017;24:3494-3501.
27.
SansoniERGrossND. The role of transoral robotic surgery in the management of oropharyngeal squamous cell carcinoma: a current review. Curr Oncol Rep. 2015;17:1-7.
28.
CannonRBHoultonJJPatelS, et al. Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS). Oral Oncol. 2018;86:296-300.
29.
MeshmanJWangPChinR, et al. Prognostic significance of p16 in squamous cell carcinoma of the larynx and hypopharynx. Am J Otolaryngol Head Neck Med Surg. 2017;38:31-37.
30.
HobelmannKCTopfMCBar-AdV, et al. AJCC-8ed nodal staging does not predict outcomes in surgically managed HPV-associated oropharyngeal cancer. Oral Oncol. 2018;82:138-143.
31.
UkpoOCPritchettCVLewisJE, et al. Human papillomavirus–associated oropharyngeal squamous cell carcinomas: primary tumor burden and survival in surgical patients. Ann Otorhinolaryngol. 2009;118(5):368-373.
32.
AminiAJasemJJonesBL, et al. Predictors of overall survival in human papillomavirus–associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016;56:1-7.
33.
AnYParkHSKellyJR, et al. The prognostic value of extranodal extension in human papillomavirus–associated oropharyngeal squamous cell carcinoma. Cancer. 2017;123(14):2762-2772.
34.
BauerEMazulAChernockR, et al. Extranodal extension is a strong prognosticator in the HPV positive oropharyngeal squamous cell carcinoma [published online May11, 2019]. Laryngoscope.
35.
KwonMRohJLLeeJ, et al. Extranodal extension and thickness of metastatic lymph node as a significant prognostic marker of recurrence and survival in head and neck squamous cell carcinoma. J Craniomaxillofac Surg. 2015;43:769-778.
36.
MajercakovaKValeroCLopezM, et al. Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients. Oral Oncol. 2018;77:37-42.
37.
BilimoriaKYStewartAKWinchesterDP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683-690.
38.
EdgeSBComptonCC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
39.
ChaturvediAEngelsEAndersonWGillisonML. Incidence trends for human papillomavirus–related and –unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612-619.
40.
AlviAJohnsonJT. Extracapsular spread in the clinically negative neck (N0): implications and outcome. Otolaryngol Head Neck Surg. 1996;114:65-70.
41.
JohnsonJTWagnerRLMyersEN. A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous cell carcinoma of the head and neck. Cancer. 1996;77:181-185.
42.
SnydermanNLJohnsonJTSchrammVLMyersENBedettiCDThearleP. Extracapsular spread of carcinoma in cervical lymph nodes: impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer. 1985;56:1597-1599.
43.
CarterRLBlissJMSooK-CO’BrienCJ. Radical neck dissections for squamous cell carcinomas: pathologic findings and their clinical implications with particular reference to transcapsular spread. Int J Radiat Oncol Biol Phys. 1987;13:825-832.
44.
LewisJSCarpenterDHThorstadWLZhangQHaugheyBH. Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol. 2011;24:1413-1420.
45.
MehraRAngKKBurtnessB. Management of human papillomavirus–positive and papillomavirus–negative head and neck cancer. Semin Radiat Oncol. 2012;22:194-197.
46.
SinhaPLewisJSPiccirilloJKallogjeriDHaugheyBH. Extracapsular spread and adjuvant therapy in human papillomavirus–related, p16-positive oropharyngeal carcinoma. Cancer. 2012;118(14):3519-3530.
47.
AjmaniGSNoconCCWangC-HBhayaniMK. Assessment of adjuvant therapy in resected head and neck cancer with high-risk features. Oral Oncol. 2017;74:15-20.
48.
CheraghlouSYuPKOtrembaMD, et al. Treatment deintensification in human papillomavirus–positive oropharynx cancer: outcomes from the National Cancer Data Base. Cancer. 2018;124:717-726.
